Although the importance of IL-6 in cancer disease progression is well documented, anti-IL-6 therapies such as siltuximab have not produced clinically beneficial results for the treatment of solid tumors such as prostate, colorectal, lung, and ovarian cancers, although breast cancer was not yet tested [11, 12]. Here, IL6 is linked to breast cancer.